Search Results
Highlights from ESGCT 2021: gene therapy clinical data, advances in gene editing & AAV toxicity
ESGCT 2021 highlights: AAV vector capsid modification for CNS disorders
Non-viral gene delivery & gene editing: highlights from ESGCT
ESGCT e-Seminar: Virus-free gene editing of T cells
Clinical Gene Therapy: ASGCT Indo-UK Symposium
ESGCT e-Seminars: Intellia’s Modular CRISPR/Cas9 Gene Editing Platform for the Treatment of Disease
FirstThought Focus: Adeno-Associated Virus (AAV) Vectors in Gene Therapies with Guangping Gao, PhD
ESGCT e-School: Gene Therapy – From Concept to Proof
Next gen AAV: How Can Synthetic Capsids Tackle Gene Therapy Challenges
Breaking the Wall of Risky Gene Therapy | Carmine Therapeutics
Panel: State of Play in the Vectors Arms Race: Perspective on the Future of Gene Delivery
Intellia’s Modular CRISPR/Cas9 Gene Editing Platform for the Treatment of Disease
